SCHEMBL31365016

SCHEMBL31365016

[2H]C([2H])([2H])C(Nc1cc(Br)cc(Cl)c1[N+](=O)[O-])c1ccc(Cl)cc1Cl

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPK1 P28482 1/20 0.35
MEN1 O00255 4/20 0.33
KMT2A Q03164 4/20 0.33
HTT P42858 2/20 0.33
MAPT P10636 2/20 0.33
TNF P01375 1/20 0.32
LMNA P02545 2/20 0.32
TP53 P04637 1/20 0.32
CACNA2D1 P54289 1/20 0.31
CACNA1B Q00975 1/20 0.31
CACNB1 Q02641 1/20 0.31
CACNA1C Q13936 1/20 0.31
POLB P06746 1/20 0.31
MCL1 Q07820 1/20 0.31
EEF2K O00418 1/20 0.31
CA1 P00915 1/20 0.31
CA14 Q9ULX7 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31365033 0.92 TNF (0.36) TSHRALDH1A1MAPK1MEN1KMT2A
SCHEMBL31365010 0.92 TSHR (0.40) TSHRALDH1A1MAPK1MEN1KMT2A
SCHEMBL31364929 0.85 TNF (0.37) TSHRALDH1A1MAPK1MEN1KMT2A
SCHEMBL31365011 0.82 MEN1 (0.36) TSHRALDH1A1MAPK1MEN1KMT2A
SCHEMBL31364824 0.80 MAPT (0.37) TSHRALDH1A1MAPK1MEN1KMT2A
SCHEMBL31365031 0.80 LMNA (0.39) TSHRMEN1KMT2AHTTMAPT
SCHEMBL15053385 0.75 TSHR (0.47) TSHRALDH1A1MAPK1MEN1KMT2A
SCHEMBL31365013 0.75 LMNA (0.37) MEN1KMT2AHTTMAPTLMNA
SCHEMBL31531593 0.75 TSHR (0.47) TSHRALDH1A1MAPK1MEN1KMT2A
SCHEMBL15053383 0.75 TSHR (0.47) TSHRALDH1A1MAPK1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025056065-A1 CHEMOKINE RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION, AND USE 上海医药集团股份有限公司 2025-03-20 WO disclosed